Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7252W HIGH $20.32
Volume
51.92 K
Value Traded
199.60 K
Short % Float
1.99%
-5.18%Week
-22.46%1 Month
-47.79%3 Month
-33.7%6 Month
-77.32%5 Year
-99.06%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
35.29 M
EPS (TTM)
-1.46
P/E Ratio
-
Ent. Value
24.95 M
Total Shares
9.64 M
Float Shares
10.97 M
Insiders
18.81%
Institutions
37.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EDSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Edesa Biotech, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Edesa Biotech, Inc.
279Total events
3Upcoming
50Tier-1 (high impact)
2014 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Equity OfferingCorporate
Edesa Biotech announces proposed underwritten public offering of common shares and warrants
▲Trial InitiationEB06Trial
EB06 Phase 2 vitiligo study site activation initiated
moderate-to-severe nonsegmental vitiligosource ↗
▲Additional DataparidiprubartClinical Data
Exploratory analyses show paridiprubart mortality reduction in ARDS patients with AKI
Acute Respiratory Distress Syndrome (ARDS) with acute kidney injurysource ↗
▲Enrollment UpdateEB06Trial
EB06 Phase 2 vitiligo study recruitment expected to begin in coming weeks
moderate-to-severe nonsegmental vitiligosource ↗
▲Additional DataparidiprubartClinical Data
Exploratory analyses show paridiprubart mortality reduction in ARDS patients with AKI
Acute Respiratory Distress Syndrome (ARDS) with concurrent acute kidney injury (AKI)source ↗
◆Oral PresentationparidiprubartPresentation
Oral presentation of exploratory data from paridiprubart study in AKI at ERA Congress
Acute Kidney Injurysource ↗
▲Full ResultsparidiprubartClinical Data
Exploratory AKI data from Phase 2 and Phase 3 studies reported
acute kidney injurysource ↗
◆Oral PresentationparidiprubartPresentation
Additional data presentation on paridiprubart in AKI at ERA Congress
Acute Kidney Injurysource ↗
◆Trial InitiationEB06Trial
Preparations for Phase 2 study of EB06 in vitiligo; site activations and patient recruitment expected to begin midyear 2026
moderate-to-severe nonsegmental vitiligosource ↗
◆Oral PresentationparidiprubartPresentation
Full oral presentation of Phase 3 results at ATS 2026 International Conference
Acute Respiratory Distress Syndromesource ↗
●Oral PresentationPresentation
Edesa to participate in Respiratory Innovation Summit, ATS 2026, Dermatology Drug Development Summit, and BIO International Convention
◆Oral PresentationparidiprubartPresentation
Oral Showcase presentation at ATS 2026 Respiratory Innovation Summit
Acute Respiratory Distress Syndromesource ↗
◆Poster PresentationparidiprubartPresentation
Poster presentation at ATS 2026 Respiratory Innovation Summit
Acute Respiratory Distress Syndromesource ↗
▲Full ResultsparidiprubartClinical Data
Additional positive Phase 3 data for paridiprubart in ARDS; consistent treatment benefits across subgroups
Acute Respiratory Distress Syndromesource ↗
◆Trial InitiationEB06Trial
Site activations and patient recruitment expected to begin mid-2026
moderate-to-severe nonsegmental vitiligosource ↗
◆Enrollment CompleteEB06Trial
Enrollment anticipated to commence first at Canadian sites after CTA approval
moderate-to-severe nonsegmental vitiligosource ↗
◆Enrollment UpdateEB06Trial
Anticipates recruitment will begin by midyear 2026
moderate-to-severe nonsegmental vitiligosource ↗
◆Topline ReadoutEB06Clinical Data
Anticipates topline results available within 12 to 18 months following FDA clearance
moderate-to-severe nonsegmental vitiligosource ↗
▲Topline ReadoutparidiprubartClinical Data
Initial Phase 3 results (104 IMV patients) reported
Acute Respiratory Distress Syndromesource ↗
▲Full ResultsparidiprubartClinical Data
Expanded Phase 3 results (278 patients including IMV and non-IMV) reported
Acute Respiratory Distress Syndromesource ↗
●Oral PresentationEB06Presentation
Company sponsorship and participation at Global Vitiligo Foundation Annual Scientific Symposium
moderate-to-severe nonsegmental vitiligosource ↗
▲Primary Endpoint MetparidiprubartClinical Data
Phase 3 paridiprubart study met primary endpoint of 28-day mortality reduction in full 278-patient population
Acute Respiratory Distress Syndrome (ARDS)source ↗
▲Full ResultsparidiprubartClinical Data
Additional positive results from Phase 3 paridiprubart study reported
Acute Respiratory Distress Syndrome (ARDS)source ↗
▲Patent GrantedparidiprubartIP / Competition
Provisional patent applications filed for paridiprubart in sepsis, acute kidney injury, and pneumonia
◆Enrollment UpdateparidiprubartTrial
Enrollment ongoing in U.S. government-funded ARDS study for paridiprubart cohort (up to ~200 subjects)
Acute Respiratory Distress Syndrome (ARDS)source ↗
◆Manufacturing MilestoneEB06CMC / Inspection
Drug manufacturing data for EB06 to be submitted to FDA IND application
moderate-to-severe nonsegmental vitiligosource ↗
▲Primary Endpoint MetparidiprubartClinical Data
Phase 3 study met primary endpoint of reduced mortality at 28 days with statistical significance
Acute Respiratory Distress Syndrome (ARDS)source ↗
▲Secondary Endpoint DataparidiprubartClinical Data
Secondary endpoint of 60-day mortality also met with statistical significance
Acute Respiratory Distress Syndrome (ARDS)source ↗
●Enrollment CompleteparidiprubartTrial
Enrollment completed early for business reasons
Acute Respiratory Distress Syndrome (ARDS)source ↗
●ATM ProgramCorporate
Received $3.4 million in net proceeds from at-the-market offering program
▲Manufacturing MilestoneEB06CMC / Inspection
Manufacturing of EB06 and placebo for Phase 2 vitiligo study progressed
moderate-to-severe nonsegmental vitiligosource ↗
◆Subgroup AnalysisparidiprubartClinical Data
Evaluating subgroup data for additional efficacy signals in ARDS
Acute Respiratory Distress Syndromesource ↗
▲Enrollment MilestoneEB05Trial
First randomizations completed in government-funded platform study
Acute Respiratory Distress Syndrome (ARDS)source ↗
◆Oral PresentationPresentation
Edesa management presentation at Bloom Burton Healthcare Investor Conference
●IND SubmissionEB06IND
Anticipates submitting drug manufacturing data to FDA for IND application
moderate-to-severe nonsegmental vitiligosource ↗
▲IND ClearanceEB06IND
Anticipates FDA regulatory clearance for Phase 2 study
moderate-to-severe nonsegmental vitiligosource ↗
Past FDA Catalysts and PDUFA Decisions
How EDSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-15 | Paridiprubart (anti-TLR4 antibody) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 87%
Micro Cap(rank 573 of 658)
Percentile Rank
Edesa Biotech, Inc. faces pipeline headwinds (23/100), with $43M risk-adjusted pipeline value, led by EB01 0.2% in Allergic Contact Dermatitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EB01 0.2% Small moleculeCompletedNCT03680131 | Allergic Contact Dermatitis | Phase 2 | COMPLETED | 211 | Jan 17, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every EDSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| paridiprubart | acute kidney injury | Phase 3 | 2026-06-05 | 28 day mortality: paridiprubart plus SOC 33% (95% CI: 28% · 39%), placebo plus SOC 49% (95% CI: 41% · 57%), relative reduction 32% (nominal p<0.005); MAKE30: paridiprubart plus SOC 41% (95% CI: 36% · 46%), placebo plus SOC 53% (95% CI: 47% · 60%), relative reduction 23% (nominal p<0.005)Read More | Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nijhawan PardeepDirector, Officer (Chief Executive Officer), 10% Owner | Grant/Award | 3,378 888,062 held | $0.00 | 07/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EDSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.1 % | 4.58 M | 563.24 K |
EDSA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EDSA ranks across every disease it competes in
Competitive Position is a premium feature
See how EDSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEDSA News
EDSA▼ -17.2%on this news
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Edesa Biotech has announced the pricing of a $25 million public offering, which includes 3,870,500 common shares and warrants. The offering aims to raise capital for general corporate purposes, including research and development. The expected closing date is August 21, 2026, pending customary conditions. Guggenheim Securities is managing the offering.
Read more →EDSA▼ -17.2%on this newsshared move
Edesa Biotech Announces Proposed Public Offering
Edesa Biotech has announced a proposed public offering of its common shares and warrants. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. Proceeds will be used for general corporate purposes, including research and development. The offering is subject to market conditions and regulatory approvals.
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Edesa Biotech reported its fiscal third quarter 2026 results, highlighting the completion of preparations for its Phase 2 clinical study of EB06 in vitiligo patients. The company also noted promising exploratory data for paridiprubart in ARDS patients with acute kidney injury. Despite a reported net loss of $5.4 million, Edesa is advancing its clinical programs and engaging with potential partners for future development.
Read more →EDSA▲ +8.4%on this news· ran to +20% by day 3
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Edesa Biotech has announced a $3.5 million private placement of common shares, led by its CEO and healthcare-focused investors. The financing is expected to close around June 15, 2026, and will support the company's vitiligo program and general corporate purposes. The shares will be sold at $4.69 each for investors and $5.21 for the CEO.
Read more →EDSA▼ -23%on this news
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech has reported positive exploratory data for paridiprubart, an anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The findings indicate a significant reduction in mortality and improvements in kidney-specific outcomes. These results will be presented at the 63rd European Renal Association Congress, reinforcing the rationale for further development of paridiprubart in AKI.
Read more →EDSA▲ +32.8%on this news
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
Edesa Biotech will present new data on paridiprubart, an anti-TLR4 antibody, at the upcoming ERA Congress in Glasgow. This presentation will focus on exploratory data from a study involving patients with acute kidney injury and respiratory distress. The company aims to highlight the drug's potential in addressing a critical medical need, given the lack of targeted therapies for AKI.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2026 Results
Edesa Biotech reported its fiscal second-quarter results, highlighting progress in its clinical programs. The company is preparing for a Phase 2 study of EB06 in vitiligo and has shared encouraging data from its Phase 3 study of paridiprubart for Acute Respiratory Distress Syndrome. Despite a reported net loss, Edesa remains optimistic about its pipeline and upcoming clinical milestones.
Read more →EDSA▲ +6.1%on this news· ran to +17% by day 1
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Edesa Biotech has announced that its CEO, Dr. Par Nijhawan, will present findings from the Phase 3 study of paridiprubart at the ATS 2026 Respiratory Innovation Summit. The study demonstrated statistically significant mortality reductions in ARDS patients. The presentation is scheduled for May 15, 2026, showcasing the potential of this first-in-class anti-TLR4 antibody.
Read more →EDSA▼ -10.8%on this news
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
Edesa Biotech has announced progress on its Phase 2 clinical study of EB06 for nonsegmental vitiligo, with enrollment expected to begin in mid-2026. The company has selected JSS Medical Research as its CRO and has started outreach to clinical sites. EB06, a monoclonal antibody targeting CXCL10, aims to address the autoimmune nature of vitiligo, which currently has limited treatment options.
Read more →EDSA▲ +68%on this news· ran to +145% by day 3
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
Edesa Biotech has reported additional positive results from its Phase 3 study of paridiprubart, showing a significant reduction in 28-day mortality among a diverse patient population. The treatment demonstrated consistent benefits across various severity groups and comorbidities. Edesa plans to advance regulatory discussions and explore strategic partnerships based on these findings.
Read more →EDSAEdesa Biotech Reports Fiscal 1st Quarter 2026 Results
Edesa Biotech, Inc. has released its fiscal results for the first quarter ended December 31, 2025. The company has made strides in manufacturing its EB06 drug candidate for vitiligo, with recruitment expected to begin mid-2026, pending regulatory approvals. They also reported positive results from a Phase 3 study of their drug paridiprubart in respiratory conditions. Despite these advancements, Edesa posted a net loss of $2.2 million and faced increased operational costs compared to the previous year.
Read more →EDSAEdesa Biotech Reports Fiscal Year 2025 Results
Edesa Biotech reported its financial results for the fiscal year ended September 30, 2025, showcasing progress in its clinical programs. The company successfully completed a Phase 3 study of its monoclonal antibody paridiprubart, while also initiating preparations for a Phase 2 study of EB06 in nonsegmental vitiligo. Despite reporting a net loss of $7.2 million, Edesa highlighted improvements in their financial position and plans to seek strategic partnerships to support ongoing and future development endeavors.
Read more →EDSA▼ -6.5%on this news
Edesa Biotech Announces Upcoming Conference Schedule
Edesa Biotech, Inc. has announced its participation in several upcoming conferences, highlighting its focus on developing host-directed therapeutics for immuno-inflammatory diseases. The company is advancing its clinical pipeline, which includes treatments for conditions such as vitiligo and Acute Respiratory Distress Syndrome. Edesa's management encourages scheduling meetings during these events for further discussions.
Read more →EDSA▼ -17.9%on this news· ran to -29% by day 3shared move
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech announced positive results from its Phase 3 study of paridiprubart for treating Acute Respiratory Distress Syndrome (ARDS). The study met primary and secondary endpoints, showing significant reductions in mortality and the need for invasive mechanical ventilation. The drug demonstrated a durable survival benefit and was well-tolerated among patients. Edesa's CEO expressed optimism about the drug's potential as a standard of care for ARDS.
Read more →EDSAEdesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech reported its fiscal 3rd quarter 2025 results, highlighting progress in manufacturing for its drug candidate EB06, aimed at treating vitiligo. The company anticipates submitting drug manufacturing data to the FDA by the end of 2025. Despite a net loss reported for the quarter, management remains optimistic about the potential of EB06.
Read more →EDSAEdesa Biotech Reports Fiscal 2nd Quarter 2025 Results
Edesa Biotech, Inc. announced its fiscal results for the second quarter of 2025, revealing a focus on developing its vitiligo drug candidate, EB06. The company secured $15 million in equity financing to advance the program and has begun regulatory preparations for a Phase 2 study in the U.S. Financial results showed a reduction in operating expenses and a smaller net loss compared to the previous year. Edesa plans to participate in the upcoming BIO International Convention to enhance investor engagement and promote its initiatives.
Read more →EDSAEdesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech, Inc. will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto. The company's management is scheduled to present on May 5 at 4:00 PM ET. Edesa is focused on developing therapeutics for immuno-inflammatory diseases, with a clinical pipeline that includes candidates for vitiligo and Acute Respiratory Distress Syndrome.
Read more →EDSA▼ -5.6%on this news
Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux. Weiler brings significant experience from various roles in the biotech sector, including leadership positions at Exzell Pharma and Cipher Pharmaceuticals. CEO Par Nijhawan expressed confidence in Weiler's ability to advance the company's pipeline and strategic opportunities.
Read more →EDSA▼ -17.2%on this news
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech, Inc. reported its fiscal 1st quarter results for 2025, showing advancements in its anti-CXCL10 monoclonal antibody candidate EB06 aimed at treating vitiligo. The company is preparing for a clinical trial, with regulatory data submission expected by mid-2025. Financially, Edesa reflected a net loss of $1.6 million, though it strengthened its capital position with a $15 million capital raise. Overall, the company is optimistic about its vitiligo program and future funding opportunities, despite facing potential risks with regulatory approvals and product efficacy.
Read more →EDSA▲ +74.7%on this newsshared move
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Edesa Biotech has successfully completed a private placement, raising approximately $15 million by selling Series B-1 convertible preferred shares and common shares. The funds will primarily support the advancement of EB06, a monoclonal antibody for nonsegmental vitiligo, into Phase 2 clinical trials. The offering was led by Velan Capital, with participation from various investors.
Read more →About Edesa Biotech, Inc.
Headquarters100 SPY COURT, MARKHAM
BIOPHARMAWATCH ELITE PLUS
Trade the next EDSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime